In this session, organised and funded by Ferring Pharmaceuticals, speakers will discuss cardiovascular prevalence and risk in prostate cancer patients. The session will also explore how to identify patients at high risk of future cardiovascular events and how to manage these patients through lifestyle modifications, pharmacological intervention, and optimisation of treatment modality to improve outcomes in clinical practice.
- Dr Patrick Davey – Consultant Cardiologist at Northampton General Hospital and University of Oxford, UK
- Professor Thomas Keane – Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston, USA
Who should attend?
Urologists, medical/clinical oncologists, clinical nurse specialists, pharmacists, primary care doctors and nurses.
CLICK HERE for PI. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk/. Adverse events should also be reported to Ferring Pharmaceuticals Ltd. Tel: 0800 111 4126. Email: email@example.com
Job code: UK-FN-2100040 | DOP: September 2021
This is a promotional meeting initiated and funded by Ferring and is for Health Care Professionals only.